Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Appointment of Chief Financial Officer

Mereo BioPharma
Posted on: 07 Nov 16

London, 7 November 2016 – Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, today announces that Richard CM Jones has been appointed Chief Financial Officer of the Company and will join the Board of Directors in early 2017.


Richard joins Mereo from Shield Therapeutics plc (AIM: STX) where he has been Chief Financial Officer and Company Secretary. He was initially appointed as a Non-Executive Director at Shield in 2010 before moving to his current position in 2011 where he had a leading role establishing the finance operations and guiding Shield through its recent IPO.  Prior to this, Richard had a career in investment banking, holding senior positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC in 1991.


Richard Bungay, the Company’s Chief Financial Officer and Chief Operating Officer has resigned from the Board of Directors and as previously indicated will leave the Company in April 2017 in order to ensure an orderly transition.


Dr Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma Group plc commented:

“I am delighted to announce the appointment of Richard Jones as our Chief Financial Officer and to the Board of Directors. His extensive financial experience in the healthcare industry, initially as an investment banker in the sector and more recently as CFO of Shield Therapeutics, complements that of the other members of Mereo’s executive team. Following our positive debut as a listed company, the Board is confident that Richard will make a valuable and significant contribution to Mereo’s future success. ”


The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Richard Crispin Morgan Jones, aged 50 years, has been a director of the following companies during the five years preceding the date of this announcement:


Current directorships

Past Directorships

Shield Therapeutics plc

Shield Holdings AG

Iron Therapeutics Switzerland AG

Shield TX (UK) Limited

Phosphate Therapeutics Limited

Krysto Pharma Ltd

Wolverleigh Consulting Ltd


Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.


Mr Jones has no beneficial interest in the ordinary shares of the Company.


For Further Enquiries:


Mereo BioPharma Group plc

+44 (0)333 023 7319

Denise Scots-Knight, Chief Executive Officer




Nominated Adviser and Joint Broker

Cantor Fitzgerald Europe

+44 (0)20 7894 7000

Phil Davies


Will Goode




Joint Broker

RBC Capital Markets

+44 (0)20 7653 4000

Rupert Walford




Public Relations Adviser to Mereo Biopharma

FTI Consulting

+44 (0)20 3727 1000

Ben Atwell


Simon Conway


Brett Pollard

Editor's Details

Mike Wood

Last updated on: 07/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.